Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
ID: 360931Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360931
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity (R01 - Clinical Trial Not Allowed) aimed at supporting research to engineer improved stem cell-derived islet cells for replacement therapies, particularly for Type 1 Diabetes. This grant seeks to enhance the intrinsic characteristics of stem cell-derived islet cell products to improve graft viability and function, encouraging studies on engineering approaches and preclinical testing. The initiative is part of the Special Diabetes Program, which funds innovative research on the prevention, treatment, and cure of Type 1 Diabetes and its complications. Interested applicants can apply for a total estimated funding of $3 million, with an award ceiling of $500,000 per project, and must submit their applications by March 7, 2026. For further inquiries, contact Albert Hwa at NIDDK_DEM@nih.gov.

    Point(s) of Contact
    NIDDK_DEM@nih.gov
    Files
    Title
    Posted
    RFA-DK-26-306-Full-Announcement.html
    The Department of Health and Human Services (NIH) has released a new funding opportunity (RFA-DK-26-306) to support research on engineering improved stem cell-derived islet cells for replacement therapies, specifically for Type 1 Diabetes. This R01 grant,
    Similar Opportunities
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the continuation of the Collaborative Islet Transplantation Registry (CITR), aimed at collecting and analyzing data from clinical trials involving isolated human islets as a treatment for diabetes. This initiative seeks to support the research community by providing valuable data for publications, presentations, and the design of future clinical trials, while also preparing periodic reports on islet transplantation outcomes and trends. The estimated total program funding for this cooperative agreement is $700,000, with one award expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the application process, which is expected to open in July 2026. For further inquiries, potential applicants can contact Thomas L. Eggerman at eggermant@extra.niddk.nih.gov or by phone at 301-594-8813.
    New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the New Investigator Gateway Awards for Collaborative Type 1 Diabetes (T1D) Research under the R03 Small Grant Program. This funding initiative aims to support innovative research and foster talent among new investigators in T1D, allowing awardees to engage in ongoing collaborations within established research networks to enhance their understanding of significant research questions. The program emphasizes critical areas such as the human islet environment, autoimmune diabetes models, and non-invasive biomarker development, ultimately fostering long-term collaborative relationships that will advance the field. Interested applicants can apply for grants up to $100,000 per year, with applications due by 5:00 PM local time on March 6, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-009.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Integrated Islet Distribution Program (UC4)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for a single source cooperative agreement to continue the Integrated Islet Distribution Program (IIDP), with an estimated total funding of $3.3 million. This program aims to facilitate the distribution of human islets to biomedical researchers, thereby supporting critical research in diabetes by managing islet availability, investigator eligibility, and overseeing standardized analyses of islet preparations. Interested applicants, particularly those with expertise in live cell distribution and human islet biology, are encouraged to prepare for the upcoming application process, with the estimated synopsis posting date set for June 25, 2025, and the anticipated award date on July 1, 2026. For further inquiries, potential applicants can contact Dr. Thomas L. Eggerman at eggermant@nih.gov or by phone at 301-594-8814.
    Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Collaborative Awards to Support Microphysiological System Pilot Studies in Type 2 Diabetes Research." This initiative aims to solicit applications for research focused on microphysiological systems (MPSs) that model type 2 diabetes, encouraging collaborative investigations that combine expertise in bioengineering, diabetes biology, and human metabolism. The program is particularly significant as it seeks to advance understanding of metabolic tissue interactions and the heterogeneity of type 2 diabetes, supporting small pilot studies to generate preliminary data. The estimated total funding for this program is $1,000,000, with four awards expected, and interested applicants can reach out to Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525 for further information. The application process is anticipated to open with a synopsis posted on April 1, 2026, and close on July 5, 2026, with awards expected to be made in January 2027.
    Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trial Required)." This initiative aims to explore the efficacy and clinical effectiveness of multimodality digital health technology approaches, such as continuous glucose monitoring and telemedicine, in the remote management of diabetes. The research is crucial for enhancing the understanding of diabetes management, prevention, diagnosis, and treatment, with a focus on improving health outcomes. The NIH anticipates awarding three grants for projects lasting up to five years, with application deadlines set for November 7, 2025, and October 6, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-315.html.
    Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium through a cooperative agreement. This initiative aims to advance research on cardiovascular disease in individuals with type 1 diabetes by soliciting applications for discovery and mechanistic studies, leveraging the resources of the existing CARE-T1D consortium formed in 2024. The program is particularly focused on hypothesis-driven research utilizing multi-omics and molecular approaches, encouraging collaboration among experts in related fields such as type 2 diabetes and atherosclerosis. The estimated total funding for this program is $4.5 million, with approximately eight awards expected to be made. Interested applicants can reach out to Dr. Chandima Nishadi De Abrew Rajapakse at Chandima.rajapakse@nih.gov or by phone at 240-429-5197. The application process is set to open with a synopsis posting on April 1, 2026, and will close on July 1, 2026, with awards anticipated by March 1, 2027.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies," aimed at advancing research in diabetes control systems. This initiative seeks to overcome barriers to effective open- and closed-loop diabetes management through innovative approaches, including the development of AI/machine learning-driven tools, novel hormone delivery methods, and digital twin modeling to enhance decision support systems. With an estimated total program funding of $3 million, the NIH anticipates awarding approximately six grants, with applications expected to open in September 2025 and close by October 2025. Interested applicants can reach out to Guillermo Arreaza-Rubín at ga96b@nih.gov or call 301-594-4724 for further information.